 CDNAs share repurchase program will reduce outstanding shares by 8 based on current prices. This and managements short-term profitability ambitions warrant a rating upgrade. The company has a strong balance sheet, with enough dry powder to leverage itself into profitability as it gradually winds down its growth initiatives. 